Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care

Record ID 32018002482
Original Title: Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
Authors' objectives: To provide a high level overview of the DxcoverTM brain cancer liquid biopsy test, which uses machine learning to identify and compare patterns in the biochemical profile of serum from patients with and without brain cancer. The risk of the patient having brain cancer, based on this comparison, is calculated using computer algorithms.
Authors' results and conclusions: While initial evidence suggests that the Dxcover spectroscopic liquid biopsy test may be able to help GPs identify those patients with generic symptoms who are most likely to benefit from referral for a brain scan, further studies are needed to confirm this.
Authors' identified further reserach: Future work should examine whether the test is helpful to GPs in their routine work and determine if it leads to faster diagnosis of patients with brain cancer and, whether this, in turn, improves patient quality of life and survival.
Project Status: Completed
Year Published: 2021
Requestor: Developers of DxcoverTM?liquid biopsy test
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Scotland, United Kingdom
MeSH Terms
  • Brain Neoplasms
  • Liquid Biopsy
  • Early Diagnosis
  • Early Detection of Cancer
  • Dxcover Cancer brain
Organisation Name: Scottish Health Technologies Group
Contact Address: Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name: his.shtg@nhs.scot
Contact Email: his.shtg@nhs.scot
Copyright: Scottish Health Technologies Group
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.